market folly

Andreas Halvorsen's hedge fund firm Viking Global has filed a 13G with the SEC regarding shares of Deciphera Pharmaceuticals (DCPH).  Per the filing, Viking now owns 8.1% of the company with over 2.47 million shares.

This is a newly disclosed public equity stake for the hedge fund, however Viking had previously invested privately in the company via Series C financing.  The filing was made due to portfolio activity on October 2nd as the company just completed its initial public offering (IPO).

For more from this hedge fund, we've posted up some other recent portfolio activity from Viking Global here.

Per Google Finance, Deciphera Pharmaceuticals is "a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases. DCC-2618, an orally administered kinase switch control inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, including glioblastoma multiforme (GBM), and other solid tumors driven by pan-KIT or PDGFR alpha. DCC-3014 is an orally administered, potent and highly selective inhibitor of colony stimulating factor receptor 1 (CSF1R). Rebastinib is an orally administered, potent and selective inhibitor of the TIE2 immunokinase. Rebastinib binds potently into the switch pocket of TIE2, stabilizing the inhibitory switch and displacing the activation switch to block TIE2 signaling."